





A transcriptomic continuum of differentiation arrest identifies myeloid interface 
acute leukemias with poor prognosis  
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Supplementary Table Legends: 
Supplementary Table S1: Gene-sets used for GSEA analysis in this study (see Excel file). 
Supplementary Table S2: Details of patient cohort (see Excel file). 
Supplementary Table S3: Differential gene expression analysis comparing AML-like T-
ALLs with other T-ALLs (see Excel file). Positive values denote genes with higher expression 
in AML-like T-ALLs. 
Supplementary Table S4: Differential gene expression analysis for the comparisons of thymic 
subset populations indicated in each tab (see Excel files). 
Supplementary Table S5: ICGS output (see Excel file). First row contains sample names, 
second row the ICGS clusters, and the following rows guide genes and their normalized 
expression. The second column indicates the guide genes groups as indicated by the black and 
white bars in Figure 2A (first tab), Supplementary Figure S3A (second tab (1)) and S3C (third 
tab (2)). 
Supplementary Table S6: Genes included in the targeted NGS panel. 
Supplementary Table S7: Mutational status by NGS (see Excel file). 0 = no mutation, 1 = 
mutation of known significance, 2 = mutation of unknown significance. 
Supplementary Table S8: List of genes used for IAL score  
Supplementary Table S9: Impact of IAL score on outcome according to ELN subgroup. 
Supplementary Table S10: Comparison of clinicobiological characteristics and mutational 
profiles of cases with high and low IAL scores in the ALFA-0701 cohort (3). 
Supplemental Table S11: Univariate analyses of Overall Survival in the ALFA-0701 cohort 
(3). 
Supplementary Table S6: Genes included in the targeted NGS panel. 
Gene Transcript CCDS Description
AKT1 ENST00000554581 CCDS9994 v-akt murine thymoma viral oncogene homolog 1 
ASXL1 ENST00000375687 CCDS13201 additional sex combs like 1 (Drosophila) 
ATM ENST00000278616 CCDS31669 ataxia telangiectasia mutated 
BCL11B ENST00000345514 CCDS9949 B-cell CLL/lymphoma 11B (zinc finger protein) 
BCOR ENST00000342274 CCDS14250 BCL6 corepressor 
CARD11 ENST00000396946 CCDS5336 caspase recruitment domain family, member 11 
CCR4 ENST00000330953 CCDS2656 chemokine (C-C motif) receptor 4 
CD58 ENST00000457047 CCDS44199 CD58 molecule 
CEBPA ENST00000498907 CCDS54243 CCAAT/enhancer binding protein (C/EBP), alpha 
CNOT3 ENST00000406403 CCDS12880 CCR4-NOT transcription complex, subunit 3 
CSNK1A1 ENST00000377843 CCDS47303 casein kinase 1, alpha 1 
CTCF ENST00000264010 CCDS10841 CCCTC-binding factor (zinc finger protein) 
CUL3 ENST00000264414 CCDS2462 cullin 3 
CXCR4 ENST00000409817 CCDS33295 chemokine (C-X-C motif) receptor 4 
DDX3X ENST00000399959 CCDS43931 DEAD (Asp-Glu-Ala-Asp) box helicase 3, X-linked 
DNM2 ENST00000359692 CCDS32907 dynamin 2 
DNMT3A ENST00000264709 CCDS33157 DNA (cytosine-5-)-methyltransferase 3 alpha 
EED ENST00000263360 CCDS8273 embryonic ectoderm development 
EP300 ENST00000263253 CCDS14010 E1A binding protein p300 
ETV6 ENST00000396373 CCDS8643 ets variant 6 
EZH2 ENST00000320356 CCDS5891 enhancer of zeste homolog 2 (Drosophila) 
FAS ENST00000355740 CCDS7393 Fas cell surface death receptor 
FBXW7 ENST00000263981 CCDS3778 F-box and WD repeat domain containing 7, E3 ubiquitin protein ligase 
FLT3 ENST00000241453 CCDS31953 fms-related tyrosine kinase 3 
FYN ENST00000354650 CCDS5094 FYN oncogene related to SRC, FGR, YES 
GATA3 ENST00000379328 CCDS31143 GATA binding protein 3 
HACE1 ENST00000262903 CCDS5050 HECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1 
HNRNPA2B1 ENST00000356674 CCDS5397 heterogeneous nuclear ribonucleoprotein A2/B1 
HRAS ENST00000417302 CCDS7699 Harvey rat sarcoma viral oncogene homolog 
IDH1 ENST00000415913 CCDS2381 isocitrate dehydrogenase 1 (NADP+), soluble 
IDH2 ENST00000330062 CCDS10359 isocitrate dehydrogenase 2 (NADP+), mitochondrial 
IKZF1 ENST00000349824 CCDS69299 IKAROS family zinc finger 1 (Ikaros) 
IL7R ENST00000303115 CCDS3911 interleukin 7 receptor 
IRF4 ENST00000380956 CCDS4469 interferon regulatory factor 4 
JAK1 ENST00000342505 CCDS41346 Janus kinase 1 
JAK3 ENST00000458235 CCDS12366 Janus kinase 3 
KIT ENST00000288135 CCDS3496 v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 
KMT2A ENST00000534358 CCDS55791 lysine (K)-specific methyltransferase 2A 
KMT2D ENST00000301067 CCDS44873 lysine (K)-specific methyltransferase 2D 
KRAS ENST00000311936 CCDS8702 Kirsten rat sarcoma viral oncogene homolog 
LEF1 ENST00000379951 CCDS47122 lymphoid enhancer-binding factor 1 
NF1 ENST00000358273 CCDS42292 neurofibromin 1 
NOTCH1 ENST00000277541 CCDS43905 notch 1 
NRAS ENST00000369535 CCDS877 neuroblastoma RAS viral (v-ras) oncogene homolog 
PHF6 ENST00000332070 CCDS14639 PHD finger protein 6 
PIK3CA ENST00000263967 CCDS43171 phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha 
PIK3R1 ENST00000521381 CCDS3993 phosphoinositide-3-kinase, regulatory subunit 1 (alpha) 
POT1 ENST00000357628 CCDS5793 protection of telomeres 1 
PTEN ENST00000371953 CCDS31238 phosphatase and tensin homolog 
PTPN11 ENST00000351677 CCDS9163 protein tyrosine phosphatase, non-receptor type 11 
PTPN6 ENST00000456013 CCDS44821 protein tyrosine phosphatase, non-receptor type 6 
PTPRD ENST00000381196 CCDS43786 protein tyrosine phosphatase, receptor type, D 
RB1 ENST00000267163 CCDS31973 retinoblastoma 1 
RELN ENST00000428762 CCDS47680 reelin 
RHOA ENST00000418115 CCDS2795 ras homolog family member A 
RPL10 ENST00000424325 CCDS14746 ribosomal protein L10 
RPL5 ENST00000370321 CCDS741 ribosomal protein L5 
RUNX1 ENST00000344691 CCDS42922 runt-related transcription factor 1 
SETD2 ENST00000409792 CCDS2749 SET domain containing 2 
SF3B1 ENST00000335508 CCDS33356 splicing factor 3b, subunit 1, 155kDa 
SH2B3 ENST00000341259 CCDS9153 SH2B adaptor protein 3 
STAT3 ENST00000264657 CCDS32656 signal transducer and activator of transcription 3 (acute-phase response factor) 
STAT5B ENST00000293328 CCDS11423 signal transducer and activator of transcription 5B 
SUZ12 ENST00000322652 CCDS11270 SUZ12 polycomb repressive complex 2 subunit 
TAL1 ENST00000294339 CCDS547 T-cell acute lymphocytic leukemia 1 
TBL1XR1 ENST00000457928 CCDS46961 transducin (beta)-like 1 X-linked receptor 1 
TDRD6 ENST00000544460 CCDS55017 tudor domain containing 6 
TET2 ENST00000540549 CCDS47120 tet methylcytosine dioxygenase 2 
TET3 ENST00000409262 CCDS46339 tet methylcytosine dioxygenase 3 
TP53 ENST00000420246 CCDS45606 tumor protein p53 
WT1 ENST00000332351 CCDS7878 Wilms tumor 1 
ZEB1 ENST00000446923 CCDS44370 zinc finger E-box binding homeobox 1 
ZRSR2 ENST00000307771 CCDS14172 zinc finger (CCCH type), RNA-binding motif and serine/arginine rich 2 


























































High IAL score 
95% CI P values 
Favorable 36 0.87 0.31-2.39 0.78 
Intermediate 97 1.89 1.15-3.09 0.011 
Adverse 43 1.46 0.70-3.06 0.31 
 
According to the ELN-2010 classification (4) that was in use during the ALFA-0701 trial, 
both Intermediate-1 and Intermediate-2 subgroups were considered in a single 




Supplementary Table S10: Comparison of clinicobiological characteristics and 
mutational profiles of cases with high and low IAL scores in the ALFA-0701 cohort (3). 
 Low IAL score High IAL score P values 
Patients, N 96 96 - 
Median age, years (range) 62.0 years (50-70) 62.4 years (50-70) 0.55 
WBC, G/L (range) 6.9 (0.15-187) 4.9 (0.5-211) 0.68 
CD33 expression <70%, 
N/tested (%) 
17/67 31/70 0.031 
Cytogenetic risk, N (%)   0.003 
     Favorable 1 (1%) 3 (3%) - 
     Intermediate 72 (75%) 57 (59.5%) - 
     Adverse 12 (12.5%) 31 (32.5%) 0.002 
     NA 11 (11.5%) 5 (5%) - 
ELN RISK, N (%) - - 0.005 
     Favorable 22 14 - 
     Intermediate 51 46 - 
     Adverse 12 31 0.002 
     Not classifiable 11 5 - 
High LSC17 score, N (%) 36 (37.5%) 60 (62.5%) <0.001 
GENE MUTATIONS, 
N mutated/tested (%) 
- - - 
     NPM1 43/96 17/94 <0.001 
     FLT3-ITD 19/96 14/95 0.45 
     IDH1 8/85 12/84 0.35 
     IDH2 13/85 11/84 0.83 
     DNMT3A 26/85 20/84 0.39 
     TET2 15/85 12/84 0.68 
     WT1 3/85 6/84 0.33 
     ASXL1 8/85 10/84 0.63 
     RUNX1 6/85 17/84 0.014 
     sAML-type gene mutations * 20/85 38/84 0.004 
 
*sAML = secondary AML type mutations, including ASXL1, SRSF2, STAG2, BCOR, U2AF1, 
EZH2, SF3B1 and/or ZRSR2 (Lindsley et al. Blood 2015) (5) 
Supplementary Table S11: Univariate analyses of Overall Survival in the ALFA-
0701 cohort (3). 
Variable Patients, 
N 
HR 95% CI P values 
GO arm 278 0.82 0.61-1.10 0.19 
Age (continuous variable) 278 1.02 0.99-1.05 0.16 
WBC (continuous variable) 277 1.003 0.99-1.01 0.071 
Adverse cytogenetics* 249 2.89 2.06-4.06 <0.001 
High CD33 expression (≥70%) 200 0.86 0.60-1.23 0.41 
ELN Risk$ 249 2.19 1.71-2.80 <0.001 
High LSC17 score 192 2.45 1.71-3.53 <0.001 
NPM1 mutation 274 0.67 0.48-0.94 0.019 
FLT3-ITD mutation 275 1.06 0.72-1.57 0.76 
RUNX1 mutation 232 1.11 0.73-1.70 0.62 
sAML-type gene mutations# 232 1.17 0.85-1.62 0.34 
High IAL score 192 1.73 1.21-2.46 0.002 
 
GO = Gemtuzumab Ozogamicin. 
*Patients with cytogenetic failure were excluded, leaving 58 adverse and 191 
favorable/intermediate cases for analysis. 
$According to the ELN-2010 classification (4) that was in use during the ALFA-0701 trial, 
both Intermediate-1 and Intermediate-2 subgroups were considered in a single 
Intermediate subgroup. 16 non-classifiable patients were excluded from the analysis. 
#sAML = secondary AML type mutations, including ASXL1, SRSF2, STAG2, BCOR, U2AF1, 
EZH2, SF3B1 and/or ZRSR2 (5). 
Covariates with significant differences (highlighted in bold) were selected for 





Supplementary Figure S1: Hierarchical clustering and Principal Component 
Analysis. (A) Unsupervised hierarchical clustering (HC) of the transcriptional profiles of 
the 48 T-ALL samples in the patient cohort. AML-like cases identified by HC in Figure 1A 
are indicated in blue. (B) Principal Component Analysis (PCA) of the sample cohort of T-
ALLs and AMLs. Density of distribution of samples in each group along PC1 is indicated. 
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Supplementary Figure S2: Transcriptional profiling of human thymic 
subpopulations. (A) Flow cytometry sorting strategy for the indicated subpopulations 
isolated from human neonatal thymi.  (B-C) Transcriptional profiling of CD34+ CD1a-
CD7- (n=3), CD34+CD1a-CD7+ (n=2), CD34+CD1a+ (n=3), CD4+ISP (n=2), Double 
Positive (DP) T-receptor (TR) Low (n=2), DP TR High (n=3) populations sorted as in (A). 
(B) number of differentially expressed genes (FDR<0.05 by limma) in pairwise 
comparisons between indicated populations. (C) PCA of indicated populations (based on 
most variable genes across all thymic populations, see methods). (D) Comparison of the 
gene expression profiles of the thymic populations analyzed here  with those of T-cells 
generated in vitro from CB CD34+ cells (6) on a 2D PCA. (E) Venn diagram showing 
overlap of genes in the Laurenti et al. ETP geneset (7) and the Early Thymic geneset 
identified here. Only 5 genes were found in both genesets: MX1, LGMN, IRF8, CXCR3 and 
OAS2. (F) and (G) ClueGO pathway analysis of genes unique to (F) the Laurenti et al ETP 
signature and (G) the Early Thymic geneset identified here. Only genesets with FDR<0.05 
are shown. 
  
Supplementary Figure S3: ICGS classifies T-ALL samples based on their stage of 
leukemic differentiation arrest. (A-B) ICGS analysis of adult samples in the Chen et al. 
dataset (1) (n=61 samples, pediatric samples were excluded). (A) Heatmap of expression 
of guide genes selected by ICGS. Genes are represented in rows. White and black bars on 
the side represent blocks of correlated genes and selected enriched gene ontology groups 
for these genes are shown. Columns represent individual T-ALL samples. Bottom bars 
indicate the phenotype of each individual sample, top bar indicates the clusters identified 
by ICGS. (B) Patient age distribution in indicated ICGS groups. * p<0.05, ** p<0.01 and *** 
p<0.001 by one-way ANOVA with multiple comparisons. Boxes indicate median, 
interquartile range and whiskers the 95 percentile. (C-E) ICGS analysis of pediatric 
samples in the Liu et al. dataset (2) (n=264 samples). (C) Heatmap of expression of guide 
genes selected by ICGS. ETP phenotype and stage of differentiation arrest (as determined 
by mutation analysis in (2)) are indicated in the bottom bars, top bar indicates the major 
clusters identified by ICGS. (D) Distribution of stages of differentiation arrest in indicated 
ICGS groups. (E) Patient age distribution in indicated ICGS groups. * p<0.05 and *** 
p<0.001 by one-way ANOVA with multiple comparisons. Boxes indicate median, 
interquartile range and whiskers the 95 percentile. (F) Enrichment of indicated normal 
hematopoietic progenitor transcriptional signatures by GSEA. Samples in the indicated 
ICGS clusters were compared to all other samples in each cohort.   NES = Normalized 
Enrichment Score, crossed out boxes indicate gene-sets that are not significantly enriched 
(FDR > 0.05). 
 
 
Supplementary Figure S4: AMLs with high IAL scores are distinct from LSC-AML and 
are enriched for lymphoid transcriptional signatures. (A) Overlap of IAL score with 
LSC17 score and (B) the extended 48 gene list from the same publication (8). Enrichment 
of MLP signatures (7) in Interface High cases by GSEA in the (C) Metzeler et al (9) and 
(D) ALFA-1701 (3) studies. These cohorts had overlap in significant differential 
expression of B-lymphoid genes from the MLP signature, as shown in the Venn diagram 
in (E) and in the heatmaps in (F) Metzeler et al (9) and (G) ALFA-1701 (3). 
  
Supplementary Methods: 
Microarray experiments: RNA was extracted from acute leukemia and normal thymic 
samples using either the RNeasy Micro or Mini Kits (Qiagen), depending on cell numbers. 
Biotinylated double strand cDNA targets were prepared from 0.3 to 35 ng of total RNA 
using the NuGEN Ovation Pico WTA System V2 Kit (Cat # 3302) followed by the NuGEN 
Encore Biotin Module Kit (Cat # 4200) according to manufacturer recommendations. 
Following fragmentation, 4.5 μg of cDNAs were hybridized for 16 hours at 450C, 60 rpm 
on Human GeneChip® HG-U133 plus 2.0 arrays (Affymetrix).  The chips were washed 
and stained in the GeneChip® Fluidics Station 450 (Affymetrix) using the FS450_0004 
script and scanned with the GeneChip® Scanner 3000 7G (Affymetrix) at a resolution of 
1.56 µm. Raw data (.CEL Intensity files) were extracted from the scanned images using 
the Affymetrix GeneChip® Command Console (AGCC) version 4.1.2. CEL files were 
further processed with Affymetrix Expression Console software version 1.4.1 to calculate 
probeset signal intensities, using Robust Multi-array Average (RMA) algorithms with 
default settings. 
Next-generation sequencing: Nextera XT (Illumina) DNA Libraries were prepared 
according to the manufacturer’s instructions and sequenced using the Illumina MiSeq 
sequencing system. The custom NGS panel (Supplementary Table S4) was originally 
inspired by the repertoire of genes found to be preferentially altered in pediatric ETP-
ALL (10), and we have previously reported analyses of other T-ALL cohorts using this 
panel (11, 12). Sequencing reads were analyzed using institutional software for 
alignment and mutation calling (Polyweb, Institut Imagine, Paris). Variant calling 
required ≥50 total reads including ≥10 alternative reads and additional visual 
confirmation in Integrative Genomics Viewer 
(https://software.broadinstitute.org/software/igv/). Variants were further filtered by 
reference to both constitutional (dbSNP, https://www.ncbi.nlm.nih.gov/snp/, ExAC, 
http://exac.broadinstitute.org/, The 1000 Genomes Browser, 
https://www.internationalgenome.org/1000-genomes-browsers/) and somatic 
(COSMIC https://cancer.sanger.ac.uk/cosmic) databases, and by prediction of 
mutational effect using the Polyphen (http://genetics.bwh.harvard.edu/pph2/), SIFT 
(https://sift.bii.a-star.edu.sg/) and Cadd (https://cadd.gs.washington.edu/score) tools.  
Data comparison with published datasets: Expression data from the LT-HSC, MLP, CMP, 
GMP, MEP, earlyB, proB umbilical cord blood (CB) populations from Laurenti et al(7) 
(GSE42414) were used to determine a list of highly variable genes across all umbilical 
cord blood populations (CB-HVGs, 7271 genes, defined as genes differentially expressed 
between any 2 populations). Microarray data from these genes was extracted from the 
AML/T-ALL dataset and was combined with the selected samples from GSE42414, batch 
corrected (using the ComBat function from the sva package) and normalised 
(normalize.quantiles function from the preprocessCore v1.34.0 package). PCA analysis 
was performed as above on these CB-HVGs for normal CB populations and T-ALL 
samples. Expression data from samples in Cante-Barret et al (6) (GSE79379) was 
combined with data from thymic populations, AMLs and T-ALLs  profiled here and batch 
corrected (using the ComBat function from the sva package). Combined PCA analysis was 
performed as described in the main methods section. 
Isolation of thymic subpopulations: Informed consent was given for provision of normal 
human thymi removed during neonatal cardiac surgery at Hôpital Necker-Enfants 
Malades. Mononuclear cell suspensions were obtained by dissection and irrigation of 
thymic tissue, followed by Ficoll gradient centrifugation. Subpopulations were isolated 
by fluorescence activated cell sorting (FACS Aria, Becton Dickinson) using the strategy 
shown in Supplementary Figure S3. The following antibodies were used: CD1a FITC  
NA1/34 Dako F714101-2; CD3 AF700  UCHT1 BD Biosciences 557943; CD3 APC  UCHT1 
BD Biosciences 555335; CD34 APC  8G12 BD Biosciences 345804; CD4 V450  (Horizon)  
RPA-T4 BD Biosciences 560345; CD4 V450  (Horizon)  RPA-T4 BD Biosciences 560345; 
CD45 V500 (Horizon)  HI30 BD Biosciences 560777; CD7 PE  M -T701 BD Biosciences 
332774; CD8 PE-Cy7  SK1 BD Biosciences 335822; TCR alpha / beta PE  IP26A Beckman 
Coulter B49177; TCR gamma / delta PE  11F2 BD Biosciences 333141. For thymic 
subpopulations CD34+CD1a-CD7-, CD34+CD1a-CD7+, CD34+CD1a+ and CD4+ ISP, FACS 
sorting was preceded by CD3+ cell depletion using magnetic activated cell sorting (MACS, 
Miltenyi Biotec). 
Calculation of IAL score: An AML interface leukemia probeset was defined as the top 100 
probes (ranked by t statistic) differentially expressed between AML samples of ICGS 
cluster 2 and 3 (interface AMLs) and those in ICGS clusters 4 and 5.  The interface score 
for each sample in each of the 2 independent cohorts (3, 9) was calculated as the Sum of 
mean-centered log2 values for each of the genes in the AML interface leukemia probeset 
(71 genes in (9), 82 in (3)). Patient samples in each cohort were split into interface HI and 
interface LO based on whether their individual interface score was above or below a 
threshold, set as the median of the interface score for that cohort (median interface score: 
-5.12 in (9), -10.17 in (3).  The robustness of the approach was tested by varying this 
threshold: similar prognostic results were obtained for any threshold between -15 and 6 
for (9), and -80 and 92 in (3). 
Outcome analyses: Post-hoc analyses of Overall (OS) and Event-free survival (EFS) of 
patients with AML were performed on publicly available data (9) and on the ALFA-1701 
cohort that we have previously reported (3). Statistical analyses and survival curves were 
calculated in R with the survival package functions survfit, survdiff and coxph (Cox model). 
For clinicobiological comparisons of IAL High and Low cases in the ALFA-1701 cohort, 
ELN risk was defined according to the ELN-2010 classification (4), and secondary AML-
type genes were defined as previously reported (5). Cytogenetic subgroups were defined 
as previously described (3), briefly: Favorable included t(8;21) and inv(16)/t(16;16); 
Adverse included monosomy 5 or del(5q), monosomy 7 or del(7q), t(6;11), t(9;22), 3q26 
abnormalities (except t(3;5)), 11q23 abnormalities (except t(9;11)), and complex 
karyotypes with 3 abnormalities or more; while the Intermediate group included all 
other anomalies as well as normal karyotypes. Covariates selected for multivariate 
analyses (Table 1) were selected based on the results of univariate analyses 
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